Molecular pathogenesis of rhabdomyosarcoma

Cancer Biology and Therapy

Volumn 1, Issue 2, 2002, Pages 97-104

  Xia, Shujuan J ^a   Pressey, Joseph G ^a   Barr, Frederic G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allelic loss; Beckwith Wiedemann syndrome; Chromosomal translocations; Gene amplification; Rhabdomyosarcoma

Indexed keywords

DNA BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1A PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HYBRID PROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN; PAX3 PROTEIN, MOUSE; PAX7 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX7;

BECKWITH WIEDEMANN SYNDROME; CHROMOSOME 11; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; PHYSIOLOGY; REVIEW; RHABDOMYOSARCOMA;

BECKWITH-WIEDEMANN SYNDROME; CHROMOSOMES, HUMAN, PAIR 11; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; RECOMBINANT FUSION PROTEINS; RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 0036491040     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.51     Document Type: Review

References (83)

1. Kramer S, Meadows AT, Jarrett P, Evans AE. Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst 1983; 70(1):49-55. (Pubitemid 13138332)
2. Tsokos M, Webber BL, Parham DM, Wesley RA, Miser A, Miser JS et al. Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med 1992; 116:847-55.
3. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997; 19:483-91. (Pubitemid 28099078)
4. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 3:113-7. (Pubitemid 23079791)
5. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54:2869-72. (Pubitemid 24187765)
6. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJd, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma [published erratum appears in Nat Genet 1994;6(2):214]. Nat Genet 1993; 5:230-5.
7. Barr FG, Nauta LE, Hollows JC. Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 1998; 102:32-9. (Pubitemid 28129056)
8. Davis RJ, Bennicelli JL, Macina RA, Nycum LM, Biegel JA, Barr FG. Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. Hum Mol Genet 1995; 4:2355-62.
9. Fitzgerald JC, Scherr AM, Barr FG. Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 2000; 117:37-40. (Pubitemid 30099653)
10. Bennicelli JL, Advani S, Schafer BW, Barr FG. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 1999; 18:4348-56. (Pubitemid 29392375)
11. Bennicelli JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1996; 93:5455-9. (Pubitemid 26159471)
12. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995; 15:1522-35.
13. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1997; 94:8047-51. (Pubitemid 27343774)
14. del Peso L, Gonzalez VM, Hernandez R, Barr FG, Nunez G. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/ threonine kinase Akt. Oncogene 1999; 18:7328-33. (Pubitemid 30032113)
15. Scheidler S, Fredericks WJ, Rauscher FJ 3rd, Barr FG, Vogt PK. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA 1996; 93:9805-9. (Pubitemid 26296690)
16. Lam PY, Sublett JE, Hollenbach AD, Roussel MF. The oncogenic potential of the Pax3- FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 1999; 19:594-601. (Pubitemid 29018461)
17. Anderson J, Ramsay A, Gould S, Pritchard-Jones K. Pax3-fkhr induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol 2001; 159:1089-96. (Pubitemid 32847199)
18. Fredericks WJ, Ayyanathan K, Herlyn M, Friedman JR, Rauscher FJ, 3rd. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Molecular & Cellular Biology 2000; 20:5019-31.
19. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ, 3rd, Schafer BW. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 1996; 93:13164-9. (Pubitemid 26382787)
20. Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E, Rauscher FJ, 3rd. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Research 2000; 60:5803-14.
21. Margue CM, Bernasconi M, Barr FG, Schafer BW. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene 2000; 19:2921-9. (Pubitemid 30389082)
22. Epstein JA, Lam P, Jepeal L, Maas RL, Shapiro DN. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 1995; 270:11719-22.
23. Anderson MJ, Shelton GD, Cavenee WK, Arden KC. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci USA 2001; 98:1589-94. (Pubitemid 32165543)
24. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 1999; 96:13264-9.
25. Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee WK. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985; 316:330-4. (Pubitemid 15237805)
26. Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 1987; 329:645-7. (Pubitemid 17140118)
27. Loh WE, Jr., Scrable HJ, Livanos E, Arboleda MJ, Cavenee WK, Oshimura M, Weissman BE. Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 1992; 89:1755-9.
28. Koi M, Johnson LA, Kalikin LM, Little PF, Nakamura Y, Feinberg AP. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11. Science 1993; 260:361-4. (Pubitemid 23160146)
29. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, Sapienza C. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA 1989; 86:7480-4. (Pubitemid 19254480)
30. Tycko B. Genomic imprinting: Mechanism and role in human pathology. Am J Pathol 1994; 144:431-43. (Pubitemid 24176745)
31. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumour-suppressor activity of H19 RNA. Nature 1993; 365:764-7. (Pubitemid 23339885)
32. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9:650-62.
33. Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, et al. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA 1996; 93:3026-30.
34. Hoovers JM, Kalikin LM, Johnson LA, Alders M, Redeker B, Law DJ, et al. Multiple genetic loci within 11p15 defined by Beckwith-Wiedemann syndrome rearrangement breakpoints and subchromosomal transferable fragments. Proc Natl Acad Sci USA 1995; 92:12456-60. (Pubitemid 26014088)
35. Schwienbacher C, Sabbioni S, Campi M, Veronese A, Bernardi G, Menegatti A. et al. Transcriptional map of 170-kb region at chromosome 11p15.5: Identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc Natl Acad Sci USA 1998; 95:3873-8. (Pubitemid 28173221)
36. Thorburn MJ, Wright ES, Miller CG, Smith-Read EH. Exomphalos- macroglossiagigantism syndrome in Jamaican infants. Am J Dis Child 1970; 119:316-21.
37. Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E. The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983; 140:5-12. (Pubitemid 13121993)
38. Li M, Squire JA, Weksberg R. Molecular genetics of Wiedemann-Beckwith syndrome. Am J Med Genet 1998; 79:253-9. (Pubitemid 28447105)
39. Weksberg R, Shen DR, Fei YL, Song QL, Squire J. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet 1993; 5:143-50. (Pubitemid 23293449)
40. Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, et al. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 1996; 14:171-3. (Pubitemid 26338797)
41. Lee MP, Hu RJ, Johnson LA, Feinberg AP. Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat Genet 1997; 15:181-5. (Pubitemid 27061639)
42. Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 1996; 56:3220-4. (Pubitemid 26242966)
43. Bridge JA, Liu J, Weibolt V, Baker KS, Perry D, Kruger R, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer 2000; 27:337-44.
44. Gordon T, McManus A, Anderson J, Min T, Swansbury J, Pritchard-Jones K, et al. United kingdom Children's Cancer Study G, United Kingdom Cancer Cytogenetics G. Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. Medical & Pediatric Oncology 2001; 36:259-67.
45. Gordon AT, Brinkschmidt C, Anderson J, Coleman N, Dockhorn-Dworniczak B, Pritchard-Jones K, et al. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 2000; 28:220-6. (Pubitemid 30247000)
46. Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer 1996; 17:254-9. (Pubitemid 26424003)
47. Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ 1993; 4:1065-70. (Pubitemid 2020828)
48. Dias P, Kumar P, Marsden HB, Gattamaneni HR, Heighway J, Kumar S. N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer 1990; 45:593-6. (Pubitemid 20146113)
49. Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer 1994; 73:2231-7. (Pubitemid 24107982)
50. Hachitanda Y, Toyoshima S, Akazawa K, Tsuneyoshi M. N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol 1998; 11:1222-7. (Pubitemid 29009333)
51. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995; 95J Clin Invest:1606-11.
52. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Medical & Pediatric Oncology 2000; 35:96-103.
53. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992; 52:2243-7.
54. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233-8. (Pubitemid 120031831)
55. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 1996; 149:143-51. (Pubitemid 26230986)
56. Wurl P, Taubert H, Bache M, Kroll J, Meye A, Berger D, et al. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 1996; 69:317-23. (Pubitemid 26298298)
57. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23. (Pubitemid 28155311)
58. Iolascon A, Faienza MF, Coppola B, Rosolen A, Basso G, Della Ragione F, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer 1996; 15:217-22. (Pubitemid 26116328)
59. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990; 323:1457-62. (Pubitemid 20384954)
60. Weichselbaum RR, Beckett M, Diamond A. Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci USA 1988; 85:2106-9. (Pubitemid 24315837)
61. Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst 1991; 83:194-200.
62. Urashima M, Teoh G, Akiyama M, Yuza Y, Anderson KC, Maekawa K. Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells. Br J Cancer 1999; 79:1032-6. (Pubitemid 29087871)
63. Knudsen ES, Pazzagli C, Born TL, Bertolaet BL, Knudsen KE, Arden, et al. Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD. Cancer Res 1998; 58:2042-9. (Pubitemid 28217485)
64. Yoo J, Robinson RA. H-ras and K-ras mutations in soft tissue sarcoma: comparative studies of sarcomas from Korean and American patients. Cancer 1999; 86:58-63. (Pubitemid 29293377)
65. Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 1989; 49:6324-7. (Pubitemid 20000931)
66. Wilke W, Maillet M, Robinson R. H-ras-1 point mutations in soft tissue sarcomas. Mod Pathol 1993; 6:129-32.
67. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356:713-5.
68. Plon SE, Peterson LE. Childhood cancer, heredity, and the environment. In: Pizzo P, Poplack D, editors. Priciples and Practice of Pediatric Oncology. 3 ed. Philadelphia: Lippincott-Raven; 1997; pp.11-36.
69. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987; 66:98-113. (Pubitemid 17059640)
70. Riddle RD, Johnson RL, Laufer E, Tabin C. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell 1993; 75:1401-16. (Pubitemid 24021914)
71. Roessler E, Belloni E, Gaudenz K, Jay P, Berta P, Scherer SW, et al. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet 1996; 14:357-60.
72. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109-13.
73. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 1998; 4:619-22. (Pubitemid 28237364)
74. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989; 9:3982-91. (Pubitemid 19216289)
75. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
76. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4:1-7.
77. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94:701-6.
78. Besnard-Guerin C, Newsham I, Winqvist R, Cavenee WK. A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Hum Genet 1996;97:163-70. (Pubitemid 26034779)
79. Visser M, Sijmons C, Bras J, Arceci RJ, Godfried M, Valentijn LJ, et al. Allelotype of pediatric rhabdomyosarcoma. Oncogene 1997;15:1309-14. (Pubitemid 27429747)
80. Fain PR, Kort EN, Yousry C, James MR, Litt M. A high resolution CEPH crossover mapping panel and integrated map of chromosome 11. Hum Mol Genet 1996;5:1631-6. (Pubitemid 26328881)
81. Hu RJ, Lee MP, Connors TD, Johnson LA, Burn TC, Su K, et al. A 2.5-Mb transcript map of a tumor-suppressing subchromosomal transferable fragment from 11p15.5, and isolation and sequence analysis of three novel genes. Genomics 1997; 46:9-17. (Pubitemid 27527686)
82. Steenman M, Westerveld A, Mannens M. Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer 2000; 28:1-13. (Pubitemid 30176757)
83. Barr FG, Nauta LE, Davis RJ, Schafer BW, Nycum LM, Biegel JA. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Human Molecular Genetics 1996; 5:15-21.